FDA approves NeuroBo’s DA-1726 application to begin Phase I trial

cafead

Administrator
Staff member
  • cafead   Feb 02, 2024 at 12:32: PM
via The US Food and Drug Administration (FDA) has approved NeuroBo Pharmaceuticals’ investigational new drug (IND) application for DA-1726 to commence a Phase I clinical trial to treat obesity.

article source